[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"supportive-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:supportive-care":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,54,80,104,135,171,194,219,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644472","bridging-the-gap-in-psychosocial-care-for-cancer-survivors-100644472",false,"NCT07672314","Bridging the Gap in Psychosocial Care for Cancer Survivors","Bridging the Gap in Psychosocial Care for Cancer Survivors: Integrating Digital Screening With Navigation Call","BRIDGE","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Under oncological care at the USB for ≥9 months\n* Completion of primary cancer treatment (see definition below)\n* Attendance at routine oncological follow-up at USB\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Primary brain tumors\n* Severe cognitive impairment\n* Acute psychiatric symptoms that may impair the participant's ability to provide informed consent or comply with study procedures\n* Insufficient German language skills","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study aims to assess the feasibility and acceptability of the implementation of a routine digital psychosocial screening combined with a psycho-oncological Navigation Call for cancer survivors after completion of primary treatment with the goal to improve identification of psychosocial needs and facilitate access to supportive care.",[27,28,29,30],"Cancer Survivorship","Psychological Distress","Psycho-Oncology","Supportive Care",[32,33,34,35,36,37,38,39,40],"Cancer survivors","Survivorship care","Digital screening","Psycho-oncology","Psychosocial distress","Patient-reported outcomes (PROs)","Navigation Call","Feasibility study","Acceptability","NOT_YET_RECRUITING","2026-06-26",{"date":44,"type":45},"2026-06-29","ACTUAL",{"date":47,"type":21},"2026-07",{"date":49,"type":21},"2028-05",{"name":51,"class":52},"University Hospital, Basel, Switzerland","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100556529","clinical-decision-support-to-increase-use-of-medications-for-opioid-use-disorder-100556529","NCT06526286","Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder","Inclusion Criteria:\n\n* Primary care encounter AND\n* Current opioid prescription (not buprenorphine) and Active opioid medications over the last 90 days OR\n* Documented as on local Pain Registry \"Does the patient fit the criteria to be included on the Pain Registry?\" OR\n* Has active problem list diagnosis of long-term (current) use of opiate analgesic OR\n* Is taking \\>=90 morphine milligram equivalents (MME) per day OR\n* Prior positive toxicology screen for illicit drugs OR\n* Diagnosis of opioid use disorder\n\nExclusion Criteria:\n\n* Active cancer diagnosis in the last 1 year\n* Hospice care\u002Fpalliative care order\n* Sickle cell disease diagnosis",true,"12 Years","89 Years",{"count":64,"type":21},200000,"OBSERVATIONAL","The objective of this study is to evaluate the impact of clinical decision support (CDS) in the form of an alert to identify patients who may be at risk of opioid use disorder (OUD) and a clinical care pathway helping providers treating patients with opioid use disorder. The pathway provides health care providers with information and suggestions for screening and treatment of opioid use disorder, including treatment with medications. The 2022 Centers for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends providers asses for and treat opioid use disorder using approved medications for opioid use disorder (MOUD). This project will randomize primary care providers at the clinic level to a control arm or intervention arm. The control arm will have access to the clinical care pathway, but will not be reminded to utilize the pathway when treating a patient with opioid use disorder. The intervention arm will receive a reminder nudge about the pathway. Buprenorphine (a medication used to treat opioid use disorder) prescribing behavior of providers and outcomes of patients will be examined based on medical records data collected during routine care. The study period will be approximately 18 months.",[68,69,70,30],"Medication Abuse","Harm Reduction","Opioid Use Disorder","2026-04-20",{"date":73,"type":45},"2026-04-23",{"date":75,"type":21},"2026-06",{"date":77,"type":21},"2027-05",{"name":79,"class":52},"University of Colorado, Denver",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":53},"100631808","screening-for-supportive-care-needs-of-oncological-patients-and-professionals---evaluation-of-a-short-pro-question-set-100631808","NCT07505498","Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO: Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Capacity to give consent\n* Cancer patients\n* Sufficient understanding of the German language\n\nExclusion Criteria:\n\n* Minors\n* Lack of capacity to give consent\n* Insufficient knowledge of German",{"count":89,"type":21},900,"The systematic recording of patient-reported symptoms and health-related quality of life (patient-reported outcomes, PROs) is a central component of oncological care. Currently, however, screening for support needs in German hospitals is inconsistent and uses different assessment tools, leading to heterogeneity, redundant surveys, and limited comparability of results. This complicates standardized, patient-centered, and cross-sector care, as well as the early identification of therapy-associated side effects and support needs.\n\nThe aim of the study is to investigate the acceptance and relevance of the core set of questions from the perspective of both cancer patients and professional healthcare providers. Cancer patient acceptance will be measured by the proportion of fully completed questionnaires, while cancer patient relevance will be assessed using a feedback form. The professional perspective will be gathered through guided feedback in quality circles conducted regularly in accordance with internal standards",[92,30,93],"Patient Related Outcome Measures","Patient Reported Outcome (PRO)","RECRUITING","2026-03-29",{"date":97,"type":45},"2026-04-01",{"date":99,"type":45},"2025-12-01",{"date":101,"type":21},"2027-12-31",{"name":103,"class":52},"University Medical Center Goettingen",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100534311","phase-1-behavioral-exercise-training-to-reduce-cardiovascular-disease-risk-100534311","NCT06237179","Behavioral Exercise Training to Reduce Cardiovascular Disease Risk","Behavioral Exercise Training to Reduce Cardiovascular Disease Risk in Men Undergoing Androgen Deprivation Therapy (EXTRA-PC)","EXTRA-PC","Inclusion Criteria:\n\n* Be diagnosed with stage II\u002FIII\u002FIV prostate cancer\n* Be currently undergoing treatment with ADT (intermittent or prolonged)\n* Have completed local curative-intent treatment, including prostatectomy or definitive radiation;\n* Be \\>40 years of age up to 85;\n* Be willing to sign an informed consent with HIPAA authorization form;\n* Not have any hearing or sight impairments that result in the inability to use the telephone or hear normal conversation;\n* Must be able to join an intervention group by personal computer, smartphone or telephone call and should agree to recording of an interview;\n* Be without any serious medical condition that precludes safe participation in an exercise program;\n* Speak English\n\nExclusion Criteria:\n\n* Be unable to undergo MRI (i.e., ferromagnetic materials in body, inability to lie flat, claustrophobia);\n* Have contraindications to exercise testing;\n* Have pre-existing overt cardiovascular disease\u002Fheart failure;\n* Active illness\u002Finfection;\n* Hemoglobin \\\u003C 7.0 grams\u002FdL\n* Platelet count \\\u003C 10 x 109\u002FL","MALE","40 Years","85 Years",{"count":116,"type":21},60,[118,119],"PHASE1","PHASE2","To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak \\& 6-minute walk distance \\[6MWD\\]) among prostate cancer (PC) patients compared to controls receiving healthy living education (HLE) at 12 weeks.",[122,30],"Prostate Cancer",[122,30,124],"Exercise","2026-02-26",{"date":127,"type":45},"2026-03-02",{"date":129,"type":45},"2024-02-21",{"date":131,"type":21},"2028-01-31",{"name":133,"class":52},"Virginia Commonwealth University",2,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":53},"100612359","mouthwash-temperature-and-oral-mucositis-in-head-and-neck-radiotherapy-100612359","NCT07252557","Mouthwash Temperature and Oral Mucositis in Head and Neck Radiotherapy","Effectiveness of Different Mouthwash Temperatures on Oral Mucositis Pain and Patient Comfort During Radiotherapy for Head and Neck Cancer: A Randomized Controlled Trial","CoolRinseHNC","Inclusion Criteria:\n\n* Histologically confirmed head and neck cancer (HNC) receiving radiotherapy for the first time, with or without concurrent chemotherapy.\n* Conscious, communicative, and able to perform the rinsing procedure and complete questionnaires.\n* Provided written informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* Non-HNC diagnoses or radiotherapy to sites outside the oral\u002Foropharyngeal region.\n* Cognitive impairment or inability to complete the rinsing protocol.","20 Years","80 Years",{"count":146,"type":21},200,[24],"This single-center randomized controlled trial evaluates the effects of cold (15-20°C) versus room-temperature (30-35°C) water gargling on oral mucositis severity, pain, and comfort in patients with head and neck cancer undergoing radiotherapy. Participants will rinse their mouth four times daily for 30-60 seconds over a 6-week radiotherapy course, with follow-up for two additional weeks. The study hypothesizes that cold-water rinsing can reduce the severity of radiation-induced oral mucositis (RTOM) and pain, improve oral comfort, and minimize treatment interruptions.",[150,151,30,152,153],"Head and Neck Cancer (H&Amp;Amp;N)","Radiation-induced Oral Mucositis","Nursing Interventions","Radiotherapy Side Effects",[155,156,157,158,30,159,160,161],"Head and Neck Cancer","Radiation-Induced Oral Mucositis","Water Temperature","Cold Water Rinse","Pain Management","Radiotherapy","Nursing Intervention","2025-11-24",{"date":164,"type":45},"2025-11-26",{"date":166,"type":21},"2026-01-01",{"date":168,"type":21},"2027-03-31",{"name":170,"class":52},"Chung Shan Medical University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":60,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100607813","a-pilot-effectiveness-and-implementation-trial-of-csnat-i-in-hong-kong-100607813","NCT07193433","A Pilot Effectiveness and Implementation Trial of CSNAT-I in Hong Kong","Refinement, Pilot Implementation, and Testing of the Carer Support Needs Assessment Tool Intervention (CSNAT-I) in Hong Kong Palliative Care Settings","Inclusion Criteria\n\n* adults ≥18 years old;\n* family members taking a primary role in patient care at home as nominated by the palliative cancer patient;\n* ability to communicate in Chinese.\n\nExclusion Criteria:\n\n* paid caregivers;\n* unable to complete the questionnaire due to mental impairment determined by physicians.",{"count":116,"type":21},[24],"In this hybrid Type 1 effectiveness-implementation pilot randomized controlled trial, 60 caregivers will be randomized into either the CSNAT-I group or usual care. Preliminary effectiveness outcomes include caregiver burden, distress, and health-related quality of life. Preliminary implementation outcomes include feasibility, fidelity, appropriateness, acceptability, cost of the intervention, as well as barriers and facilitators to intervention implementation. Quantitative data will be analyzed using descriptive analysis and linear mixed effects model, while qualitative data using thematic analysis. The CSNAT-I is expected to be preliminarily effective in improving caregiver outcomes and implementable in Hong Kong palliative care context, which will serve as the foundation for a large trial before integration into daily practice.",[182,183,184,30],"Carers","Palliative Care","Needs Assessment","2025-09-18",{"date":187,"type":45},"2025-09-25",{"date":189,"type":21},"2025-09-20",{"date":191,"type":21},"2026-05-20",{"name":193,"class":52},"The Hong Kong Polytechnic University",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":53},"100562537","impact-of-acupuncture-and-integrative-medicine-on-patients-quality-of-life-during-national-emergency-and-wartime-100562537","NCT06604455","Impact of Acupuncture and Integrative Medicine on Patients Quality-of-life During National Emergency and Wartime","Impact of Acupuncture and Integrative Medicine on Patients&Amp;Amp;#39; Quality-of-life During National Emergency and Wartime in Integrative Oncology and Inpatient Settings","Inclusion Criteria:\n\n* Patients diagnosed with cancer, age ≥ 18 years who are either hospitalized or undergoing oncology treatment in an outpatient care setting; or hospitalized for any other diagnosis\n* Patients expressing quality of life related concerns affected directly or indirectly to the war and related security status.\n\nExclusion Criteria:\n\nInability to read and provide informed consent",{"count":202,"type":21},300,[24],"The current ongoing war in Israel, which began in October 2023 with a risk for spreading regionally across the Middle East, has presented a significant challenge to many patients, affecting also those receiving active oncology treatment. The present study examines a unique setting of care involving a diverse population of patients, including those receiving oncology treatment, from a widely diverse social, cultural and religious, background. Patients are offered integrative medicine treatments for 3 weeks with the goal of addressing war-related physical, emotional, and other quality of life-related concerns. After signing the informed consent form, patients will be randomly allocated to one of the two study interventions: acupressure-relaxation alone (Group A); or acupressure-relaxation modalities with acupuncture (Group B). The response to the study intervention for quality of life-related concerns will be re-assessed immediately; at 24-48 hours; and after 3 weeks following the treatment. Patients will also undergo objective measurements during treatment using Heart Rate Variability (HRV) to determine the impact of the intervention on their QoL and concerns.",[30],[207,208,209],"Integrative medicine","Integrative oncology","acupuncture","2024-09-17",{"date":212,"type":45},"2024-09-19",{"date":214,"type":45},"2024-08-28",{"date":216,"type":21},"2026-06-30",{"name":218,"class":52},"Carmel Medical Center",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100560541","the-efficacy-of-implementing-nurse-performed-ultrasound-guided-peripheral-intravenous-access-in-oncology-patients-100560541","NCT06578494","The Efficacy of Implementing Nurse-performed Ultrasound-guided Peripheral Intravenous Access in Oncology Patients","The Efficacy of Implementing Nurse-performed Ultrasound-guided Peripheral Intravenous Access in Oncology Patients: a Prospective Interventional Clinical Study","Inclusion Criteria:\n\n* Cancer patients admitted to the oncological outpatient unit are eligible for inclusion if they are scheduled for treatment with chemotherapy requiring placement of peripheral intravenous catheter, aged 18 years or older, and reside in the Faroe Islands.\n\nExclusion Criteria:\n\n* Lack of informed consent and mental incapacity.",{"count":227,"type":21},40,[24],"The purpose of this study is to investigate the clinical efficacy of nurse-performed ultrasound-guided intravenous access in oncology patients on the oncological outpatient unit in the National Hospital of the Faroe Islands.",[30],[232,233,234],"Ultrasonography","Intravenous","Oncology","2024-08-27",{"date":237,"type":45},"2024-08-29",{"date":239,"type":21},"2024-09-16",{"date":241,"type":21},"2026-02-16",{"name":243,"class":52},"Faroese Hospital System",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":251,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":53},"100558612","the-gos-frail-geriatric-oncology-supportive-care-for-frail-older-adults-with-cancer-study-100558612","NCT06553378","The GOS-Frail (Geriatric Oncology Supportive Care for Frail Older Adults With Cancer) Study","GOS-Frail","Inclusion criteria\n\n1. Age ≥ 65\n2. Diagnosis of solid organ cancer\n3. Plan for curative-intent chemotherapy and\u002For radiotherapy\n4. Clinical Frailty Scale (CFS) score ≥ 4,\n\nExclusion criteria: Evaluation by Geriatric or Palliative Medicine in the previous 6 months.","21 Years",{"count":253,"type":21},154,[24],"Background Cancer is more prevalent in older adults, but most cancer treatment trials have mainly involved young and healthy subjects. Among geriatric syndromes, frailty is a significant risk factor for negative outcomes such as treatment delays, discontinuation, and treatment-related side effects, as well as functional decline and poor survival. Research has shown that geriatric assessment with appropriate intervention can improve these outcomes, although the impact may be influenced by the inclusion of patients receiving palliative-intent treatment. Supportive care focuses on symptom assessment and treatment to enhance treatment tolerance and quality of life. To date, there have been no studies examining the combined benefits of geriatric oncology and supportive care clinics. We conducted a pilot study called Geriatric Oncology Supportive Clinic for Elderly (GOSPEL), which demonstrated an improved quality of life for older adults with curable cancer. Based on these results, we developed an enhanced care model.\n\nAim The study GOS-Frail aims to assess the effect of an integrated Geriatric Oncology Supportive Clinic on the quality of life of older adults with cancer receiving curative-intent chemotherapy and\u002For radiotherapy at 1 month.\n\nMethods The GOS-Frail study is a multi-centre, open-label, parallel-arm, randomized controlled trial conducted in the specialist outpatient clinics of two university-affiliated tertiary care hospitals. 154 adults aged 65 and above, diagnosed with solid organ cancer and planned for curative-intent chemotherapy and\u002For radiotherapy, and with a clinical frailty scale score of 4 and above, will be recruited. Subjects will be randomized to either attend a geriatric oncology supportive clinic or receive frailty education material. Quality of life questionnaires will be administered at baseline, 2 weeks, and 1, 3, 6, and 12 months from treatment initiation.\n\nHypothesis:\n\nThe GOS-Frail study investigates on the role of a synergistic geriatric oncology and supportive model of care in improving quality of life in older adults undergoing curative-intent cancer treatment.",[257,30,258],"Geriatric Oncology","Quality of Life",[257,30,258],"2024-08-13",{"date":262,"type":45},"2024-08-14",{"date":264,"type":21},"2024-09-01",{"date":266,"type":21},"2027-08-31",{"name":268,"class":52},"Tan Tock Seng Hospital"]